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survival rates having increased from 50% in the 1970s to
nearly 80% today. The reasons for the improvement are mul-
tifactorial, with major contributions made by the advent of
screening and improved systemic therapies such as anti-oes-
trogens, chemotherapy and trastuzumab. Running alongside
this improvement in breast-cancer-specific survival has been
an increasing realisation that preservation of the breast, with-
out compromise on rates of local control, is important for
quality of life. This has led to progress in techniques of breast
reconstruction and breast conservation, with oncoplastic
techniques to reshape the breast, minimising distortion and
asymmetry and increasing the use of primary systemic ther-
apy to enhance rates of conservation. Whilst surgery to the
breast itself is becoming more complex, surgery to the axilla
is becoming less extensive as there is an increasing realisa-
tion that the main value of identifying axillary disease is
not to enhance survival, or even local control, but to give
prognostic information to guide adjuvant therapies. This
drive has seen a move away from axillary clearance to senti-
nel-node biopsy, and perhaps eventually only axillary imag-
ing assessment, with the development of increasingly
sensitive tests such as magnetic resonance imaging (MRI)
and positron emission tomography (PET) [1].
The changes to practice have been driven by research evi-
dence, and the overarching theme is that of individualised
therapy. This is true of all the disciplines in the breast care
team. Surgery is now tailored to the woman’s disease, breast
shape and size and personal preferences, and in most cases
women may be offered surgery that will retain, restore or
even enhance her breasts should she so wish. Radiotherapy
is increasingly targeted to maximise the dose to the breast
whilst reducing the dose to the surrounding tissues using
highly complex computed-tomography-guided planning
(tomotherapy and intensity-modulated radiation therapy,
IMRT). Perhaps the most complex area of all is the interplaybetween the molecular pathology of the tumour and the sys-
temic therapy which is offered. Tumour stage, grade and oest-
rogen receptor status have now been supplemented with
Her2 status, and increasingly the proliferation index, Ki67,
resulting in a new classification (luminal A, B, Her2+ and
basal-like) [2] which guides prognosis and predicts treatment
response. More detailed recurrence risk assessments may be
provided by multigene arrays such as Oncotype DxTM (Geno-
mic Health, United States of America (USA)) [3] and Mamma-
PrintTM (Agendia BV, The Netherlands) [4] which may further
aid decisions about chemotherapy benefits.
The future for breast cancer treatment will hold evenmore
individualised treatment plans than the complex schedules
on offer today. Next-generation sequencing opens up the pos-
sibilities for identification of even more complex gene signa-
tures [5], which may permit customised therapies with
some of the bewildering array of targeted molecular therapies
under development. Increasing rates of complete pathological
responses to primary systemic therapy may lead to ‘no sur-
gery’ options: something which is currently being trialled in
respect of both the axilla and the breast.
Central to all of the above is the close working relation-
ship of the breast multidisciplinary team. Each must have
not only expertise in their own discipline but awareness
of what their colleagues can (and cannot) achieve, so that
every patient receives an individualised treatment plan that
fits together like a perfect jigsaw, with every piece comple-
menting the others.
The following articles have been written by some of
the world leaders in the field of breast care, and exem-
plify these principles of individualised care and
multidisciplinarity.
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